Increase in Prevalence of Cancer to Boost Graft vs Host Disease Treatment Market: Technavio

Technavio has published a new report on the global graft vs host disease (GVHD) treatment market from 2017-2021. (Photo: Business Wire)

LONDON--()--Technavio market research analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of more than 7% during the forecast period, according to their latest report.

The market study covers the present scenario and growth prospects of the global graft vs host disease treatment market for 2017-2021. The report also lists acute GVHD and chronic GVHD as the two major segments based on disease type, of which the acute GVHS dominated the market with close to 53% of the market share in 2016.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio analysts highlight the following three market drivers that are contributing to the growth of the global GVHD treatment market:

  • Increase in number of organ transplants
  • Increase in prevalence of cancer
  • Strong pipeline of expected launches

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Increase in number of organ transplants

Organ transplant is done with an intention to restore the natural functions of the body in the cases where original organs get damaged due to some disease. Organ transplantation is many times the only treatment left at the end stage of organ failures such as the heart or liver failure. The rapid growth in chronic diseases has led to strong growth in organ transplant during the last few years.

“This growing number of organ transplant is expected to fuel the global GVHD treatment market. The incidence rates of GVHD varies from organ to organ. The data estimates that the incidence rate of GVHD for various solid organ transplant varies between 1% and 6%. The prevalence is higher in small intestine transplantation. Thus, growing number of solid organ transplant is expected to fuel the global GVHD treatment market,” says Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research.

Increase in prevalence of cancer

Cancer is the second largest cause of death globally, with the prevalence of this disease growing at high rates. Bone marrow transplant is widely preferred in various types of cancers as it involves the replacement of tumor cells with healthy cells. GVHD is one of the major challenges in bone marrow transplant.

With the increasing preference for bone marrow transplant as a treatment for cancer, there has been a proportionate increase in the population of GVHD patients, which augurs well for the growth of the market during the forecast period.

Strong pipeline of expected launches

The growing prevalence of GVHD is increasing the need for various drugs for disease management. There is no specific approved drug for GVHD, and this creates a huge unmet need for drugs dedicated specifically to GVHD. Vendors are undertaking initiatives to fund R&D to resolve this issue.

“According to the pipeline landscape, there are around 14 clinical molecules in Phase II and Phase III for acute and chronic GVHD which are expected to be launched during the forecast period. These expected launches of newer drugs will boost the market during the forecast period,” says Sapna.

Drug development is a cost-intensive process; therefore, vendors are constantly looking for strategic alliances in the drug discovery phase. Such alliances and partnerships will help boost the R&D space further for GVHD treatment market, which currently witnesses the absolute lack of approved therapies. Additionally, grants by various government and NGOs are further strengthening the R&D arena. For instance, in November 2015, National Institute of Allergy and Infectious Diseases (NIAID), awarded a grant of USD 2.2 million to City of Hope, a highly rated cancer hospital in California, US. This research grant was provided exclusively to conduct studies on causes and treatment of GVHD.

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio market research analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of over 7% until 2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com